<SEC-DOCUMENT>0001193125-19-052970.txt : 20190227
<SEC-HEADER>0001193125-19-052970.hdr.sgml : 20190227
<ACCEPTANCE-DATETIME>20190227083902
ACCESSION NUMBER:		0001193125-19-052970
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20190227
FILED AS OF DATE:		20190227
DATE AS OF CHANGE:		20190227

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			InflaRx N.V.
		CENTRAL INDEX KEY:			0001708688
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			P7
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38283
		FILM NUMBER:		19635920

	BUSINESS ADDRESS:	
		STREET 1:		WINZERLAER STR. 2
		CITY:			JENA
		STATE:			2M
		ZIP:			07745
		BUSINESS PHONE:		49 3641 508180

	MAIL ADDRESS:	
		STREET 1:		WINZERLAER STR. 2
		CITY:			JENA
		STATE:			2M
		ZIP:			07745

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Fireman B.V.
		DATE OF NAME CHANGE:	20170606
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d714747d6k.htm
<DESCRIPTION>6-K
<TEXT>
<HTML><HEAD>
<TITLE>6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">6-K</FONT> </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Report of
Foreign Private Issuer </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to Rule <FONT STYLE="white-space:nowrap">13a-16</FONT> or
<FONT STYLE="white-space:nowrap">15d-16</FONT> of </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>the Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>February 2019 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number: <FONT STYLE="white-space:nowrap">001-38283</FONT> </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>InflaRx N.V. </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Winzerlaer
Str. 2 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>07745 Jena, Germany </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(+49) 3641 508180 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive offices) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether
the registrant files or will file annual reports under cover of Form <FONT STYLE="white-space:nowrap">20-F</FONT> or Form <FONT STYLE="white-space:nowrap">40-F.</FONT> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form <FONT STYLE="white-space:nowrap">20-F&nbsp;&nbsp;&#9746;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form</FONT>
<FONT STYLE="white-space:nowrap">40-F&nbsp;&nbsp;&#9744;</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form <FONT
STYLE="white-space:nowrap">6-K</FONT> in paper as permitted by Regulation <FONT STYLE="white-space:nowrap">S-T</FONT> Rule 101(b)(1):&nbsp;&nbsp;&#9744; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form <FONT STYLE="white-space:nowrap">6-K</FONT> in paper as permitted by Regulation <FONT
STYLE="white-space:nowrap">S-T</FONT> Rule 101(b)(7):&nbsp;&nbsp;&#9744; </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INFLARX N.V. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On February&nbsp;27, 2019 InflaRx N.V. issued a press release titled &#147;InflaRx Receives Approval to Initiate Phase IIa Clinical Trial with Lead Candidate <FONT
STYLE="white-space:nowrap">IFX-1</FONT> in Pyoderma Gangraenosum.&#148; A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. <B></B> </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized, in the City of Jena, Germany, February&nbsp;27, 2019. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="80%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5">INFLARX N.V.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Niels Riedemann</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Niels Riedemann</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Executive Officer</TD></TR>
</TABLE></DIV>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT INDEX </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; ">Exhibit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman">Description of Exhibit</P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press release dated February&nbsp;27, 2019.</TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d714747dex991.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML><HEAD>
<TITLE>Exhibit 99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="justify">


<IMG SRC="g714747g0226185006914.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; line-height:22.0pt; font-size:16pt; font-family:ARIAL" ALIGN="center">InflaRx Receives Approval to
Initiate Phase IIa Clinical Trial with Lead Candidate <FONT STYLE="white-space:nowrap">IFX-1</FONT> in Pyoderma Gangraenosum </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="justify"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; line-height:18.0pt; font-size:12pt; font-family:ARIAL" ALIGN="justify">&#149;</P></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; line-height:18.0pt; font-size:12pt; font-family:ARIAL" ALIGN="justify"><I>Third autoimmune disease being evaluated with <FONT STYLE="white-space:nowrap">IFX-1</FONT> </I>
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="justify"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; line-height:18.0pt; font-size:12pt; font-family:ARIAL" ALIGN="justify">&#149;</P></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; line-height:18.0pt; font-size:12pt; font-family:ARIAL" ALIGN="justify"><I>Pyoderma Gangraenosum is a debilitating, rare autoimmune disease marked by large, painful
ulcers</I> </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; line-height:16.0pt; font-size:11pt; font-family:ARIAL" ALIGN="justify"><B>Jena, Germany, February</B><B></B><B>&nbsp;27, 2019 &#150; InflaRx N.V. </B>(Nasdaq: IFRX), an
innovative biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, today announced the approval of a Clinical Trial Application by Health Canada for a phase IIa clinical trial evaluating the
Company&#146;s lead product candidate, <FONT STYLE="white-space:nowrap">IFX-1,</FONT> in Pyoderma Gangraenosum. This is the third autoimmune disease for which InflaRx is developing <FONT STYLE="white-space:nowrap">IFX-1.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; line-height:16.0pt; font-size:11pt; font-family:ARIAL" ALIGN="justify">Pyoderma Gangraenosum (PG) is a rare and debilitating neutrophilic-driven, autoinflammatory disease, characterized by an acute,
destructive ulcerating process of the skin, primarily occurring on the legs. The exact prevalence of PG is not yet known, but it is estimated that up to 50,000 patients in the US and Europe are affected by this disease. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; line-height:16.0pt; font-size:11pt; font-family:ARIAL" ALIGN="justify">&#147;Pyoderma Gangraenosum is a debilitating disease with limited treatment options and frequent recurrence of open leg
ulcers,&#148; said Othmar Zenker, M.D., Chief Medical Officer of InflaRx. &#147;Given the role that neutrophils appear to play in this disease, we believe that <FONT STYLE="white-space:nowrap">IFX-1,</FONT> which targets a key inflammatory-causing
protein that binds to these cells, has the potential to play a role in combatting PG. We are pleased to have received approval to initiate a clinical trial, and our team is excited to evaluate the safety and efficacy of <FONT
STYLE="white-space:nowrap">IFX-1</FONT> in this indication.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; line-height:16.0pt; font-size:11pt; font-family:ARIAL" ALIGN="justify">The phase IIa study is an open label study to evaluate <FONT
STYLE="white-space:nowrap">IFX-1</FONT> in approximately 12 patients with moderate to severe PG. The study is anticipated to initially be conducted at 3 sites in Canada. <FONT STYLE="white-space:nowrap">IFX-1</FONT> will be administered over a <FONT
STYLE="white-space:nowrap">12-week</FONT> period. The main objectives of the study are to evaluate the safety of <FONT STYLE="white-space:nowrap">IFX-1,</FONT> as well as to achieve clinical proof of concept based on relevant efficacy parameters.
Trial enrolment is planned to start in the second quarter of 2019. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; line-height:16.0pt; font-size:11pt; font-family:ARIAL" ALIGN="justify"><B><FONT STYLE="white-space:nowrap">IFX-1:</FONT> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; line-height:16.0pt; font-size:11pt; font-family:ARIAL" ALIGN="justify"><FONT STYLE="white-space:nowrap">IFX-1</FONT> is a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> monoclonal anti-complement factor C5a antibody which highly and effectively blocks the biological activity of C5a and demonstrates high selectivity
towards its target in human blood. Thus, <FONT STYLE="white-space:nowrap">IFX-1</FONT> leaves the formation of the membrane attack complex <FONT STYLE="white-space:nowrap">(C5b-9)</FONT> intact as an important defense mechanism, which is not the
case for molecules blocking the cleavage of C5. <FONT STYLE="white-space:nowrap">IFX-1</FONT> has been demonstrated to control the inflammatory response driven tissue and organ damage by specifically blocking C5a as a key &#147;amplifier&#148; of
this response in <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies. <FONT STYLE="white-space:nowrap">IFX-1</FONT> is believed to be the first monoclonal <FONT STYLE="white-space:nowrap">anti-C5a</FONT> antibody introduced into clinical
development and has, to date, successfully completed three clinical phase II studies. More than 150 people have been treated with <FONT STYLE="white-space:nowrap">IFX-1</FONT> in these completed clinical trials, and the antibody has been shown to be
well tolerated. <FONT STYLE="white-space:nowrap">IFX-1</FONT> is currently being developed for various inflammatory indications, including Hidradenitis Suppurativa and ANCA-associated vasculitis. </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="justify">


<IMG SRC="g714747g0226185006914.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; line-height:16.0pt; font-size:11pt; font-family:ARIAL" ALIGN="justify"><B>About InflaRx N.V.: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; line-height:16.0pt; font-size:11pt; font-family:ARIAL" ALIGN="justify">InflaRx (Nasdaq: IFRX) is a clinical-stage biopharmaceutical company focused on applying its proprietary <FONT
STYLE="white-space:nowrap">anti-C5a</FONT> technology to discover and develop <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class,</FONT></FONT> potent and specific inhibitors of C5a. Complement C5a is a powerful
inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. InflaRx was founded in 2007 and has offices and subsidiaries in Jena and Munich, Germany, as well as Ann Arbor, MI and New York, NY,
USA. For further information please visit www.inflarx.com. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; line-height:16.0pt; font-size:11pt; font-family:ARIAL" ALIGN="justify"><B>Contacts: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; line-height:16pt; font-size:11pt; font-family:ARIAL" ALIGN="justify"><B>Investor Relations </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; line-height:16pt; font-size:11pt; font-family:ARIAL" ALIGN="justify"><B>InflaRx N.V. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; line-height:16pt; font-size:11pt; font-family:ARIAL" ALIGN="justify">Jordan Silverstein </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; line-height:16pt; font-size:11pt; font-family:ARIAL" ALIGN="justify">Head of Corporate Development and Strategy </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; line-height:16pt; font-size:11pt; font-family:ARIAL" ALIGN="justify">jordan.silverstein[at]inflarx.de </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; line-height:16pt; font-size:11pt; font-family:ARIAL" ALIGN="justify">+1 917 837 1709 </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; line-height:16pt; font-size:11pt; font-family:ARIAL" ALIGN="justify"><B>Media Relations </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; line-height:16pt; font-size:11pt; font-family:ARIAL" ALIGN="justify"><B>MC Services AG </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; line-height:16pt; font-size:11pt; font-family:ARIAL" ALIGN="justify">Katja Arnold, Laurie Doyle, Andreas Jungfer </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; line-height:16pt; font-size:11pt; font-family:ARIAL" ALIGN="justify">Email: <FONT STYLE="white-space:nowrap">inflarx[at]mc-services.eu</FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; line-height:16pt; font-size:11pt; font-family:ARIAL" ALIGN="justify">Tel: +49 89 210 2280 </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; line-height:16pt; font-size:11pt; font-family:ARIAL" ALIGN="justify">FORWARD LOOKING STATEMENTS </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; line-height:16pt; font-size:11pt; font-family:ARIAL" ALIGN="justify">This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking
statements, which are often indicated by terms such as &#147;may,&#148; &#147;will,&#148; &#147;should,&#148; &#147;expect,&#148; &#147;plan,&#148; &#147;anticipate,&#148; &#147;could,&#148; &#147;intend,&#148; &#147;target,&#148;
&#147;project,&#148; &#147;estimate,&#148; &#147;believe,&#148; &#147;estimate,&#148; &#147;predict,&#148; &#147;potential&#148; or &#147;continue&#148; and similar expressions. Forward-looking statements appear in a number of places throughout this
release and may include statements regarding our intentions, beliefs, projections, outlook, analyses and current expectations concerning, among other things, our ongoing and planned preclinical development and clinical trials, the timing of and our
ability to make regulatory filings and obtain and maintain regulatory approvals for our product candidates, our intellectual property position, our ability to develop commercial functions, expectations regarding clinical trial data, our results of
operations, cash needs, financial condition, liquidity, prospects, future transactions, growth and strategies, the industry in which we operate, the trends that may affect the industry or us and the risks uncertainties and other factors described
under the heading &#147;Risk Factors&#148; in InflaRx&#146;s periodic filings with the Securities and Exchange Commission. These statements speak only as of the date of this press release and involve known and unknown risks, uncertainties and other
important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Given these risks, uncertainties
and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future, except as required by law.
</P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g714747g0226185006914.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g714747g0226185006914.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  O )<# 2(  A$! Q$!_\0
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0O_$I!]#FKU% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
